Depiction of lyophilized vials of VEGF-165 Human, E. coli Recombinant Protein.

VEGF-165 Human, E. coli Recombinant Protein

A32410010
Regular price
$195.00
Sale price
$195.00
Regular price
$231.00
Unavailable
Unit price
per 
Shipping calculated at checkout.

Description

Our bioactive VEGF-165 Human, E. coli Recombinant Protein is a double, non-glycosylated, polypeptide chain that contains 165 amino acids and has a molecular mass of 38.2 kDa. The VEGF-165 is purified by proprietary chromatographic techniques.

Summary

Vascular endothelial growth factor (VEGF), also known as VEGF-A, is an important signaling protein involved in both vasculogenesis and angiogenesis. As its name implies, VEGF activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (e.g. stimulation monocyte/macrophage migration, neurons, cancer cells, kidney epithelial cells ).

VEGF mediates increased vascular permeability, induces angiogenesis, vasculogenesis and endothelial cell growth, promotes cell migration, and inhibits apoptosis. In vitro, VEGF has been shown to stimulate endothelial cell mitogenesis and cell migration. VEGF is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor.

Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy.

Alternately spliced VEGF isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) are expressed in humans, with VEGF-165 being known to be the most abundant and potent isoform.

Other Names

VEGF-A, VEGFA, Vascular endothelial growth factor (VEGF), Vascular Endothelial Growth Factor 165, VEGF165, VEGF 165, Vascular permeability factor (VPF), UniProtKB# P15692 

Source

Expressed in E. coli.

Formulation

Sterile-filtered, white, lyophilized (freeze-dried) powder. VEGF-165 protein was lyophilized from a concentrated (1 mg/ml) solution with no additives.

Amino Acid Sequence

APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR.

Purity

Purity greater than 95.0% as determined by:

  1. Analysis by RP-HPLC.
  2. Analysis by SDS-PAGE.

Protein Content

VEGF-165 protein quantitation was carried out by two independent methods:

  1. UV spectroscopy at 280 nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1 mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
  2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard.

Biological Activity

Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 3.7-5.6 ng/ml, corresponding to a Specific Activity of 178,570-270,270 IU/mg.

Reconstitution

It is recommended to reconstitute the lyophilized VEGF-165 in sterile 18MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Shipping

Ships at ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Lyophilized VEGF-165, although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution, VEGF-165 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Usage

This product is intended for Laboratory Research Use Only. Not for use in diagnostic or therapeutic procedures. This product may not be used as a pharmaceutical or veterinary drug, agricultural product, or food additive.

Documents

Related Products